undamentalytics Newsletter
Sign in

Nurix Therapeutics, Inc. revenue

Nurix Therapeutics, Inc.'s revenue was $84.0m in fiscal 2025, up 54.0% on the year before. Since fiscal 2019 ($31.1m) it has grown at a compound 18.0% a year. Over the last twelve months it was $702m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Nov 20192020Nov 20202021Nov 20212022Nov 20222023Nov 20232024Nov 20242025Nov 2025LTMAug 2026
Revenue31183039775584702
Growth on the year before—−42.7%+66.9%+29.8%+99.3%−29.1%+54.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to November 30, 2025
Products and services
Line of business Revenue Share YoY
Collaboration Revenue $54M 64.3% ▼ 1.0%
License Revenue $30M 35.7% —

From Nurix Therapeutics, Inc.'s 10-K filed January 28, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Nurix Therapeutics, Inc. $702m 738.8% 117.1%
Ultragenyx Pharmaceutical Inc. $717m 17.5% 21.2%
Arrowhead Pharmaceuticals, Inc. $669m 16.8% 37.7%
Mirum Pharmaceuticals, Inc. $618m 44.0% 74.8%
TG Therapeutics, Inc. $800m 76.1% 221.5%
Telix Pharmaceuticals Ltd $804m 55.6% —

Compare with peers

Head to head: NRIX vs RAREARWR vs NRIXMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nurix Therapeutics, Inc.